Quel est le prix pour EQRx, Inc. (EQRX)

Le prix pour EQRx, Inc. (EQRX) est $2.34

Quelle est la capitalisation boursière pour EQRx, Inc. (EQRX)

La capitalisation boursière pour EQRx, Inc. (EQRX) est $728.90M

EQRx, Inc. (EQRX) Ratio P/B

EQRx, Inc. is a U.S.-based pharmaceutical firm dedicated to innovating therapies, predominantly for oncological (cancer) and immune-inflammatory conditions. The company's late-stage pipeline features two promising drug candidates in Phase III clinical trials: Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor specifically for patients with EGFR-mutated non-small cell lung cancer (NSCLC), and Sugemalimab, an anti-programmed death-ligand 1 antibody aimed at treating Stage III and Stage IV NSCLC. Its broader developmental portfolio encompasses a range of additional clinical and pre-clinical assets. This portfolio includes Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor in Phase II trials for metastatic breast cancer; EQ176, an anti-programmed death-1 antibody undergoing Phase III development for primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor currently in various Phase I studies. Established in 2019, EQRx maintains its corporate headquarters in Cambridge, Massachusetts.

Année	Ratio P/B	Changez
Pas assez de données pour les dates fournies.

Année

Ratio P/B

Changez

Pas assez de données pour les dates fournies.

Entreprise	Ratio P/B	Différence de Ratio P/B	Pays
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	-	US
Argenx SE ARGX.US	6.2413	-	NL
CSL Limited CSL.AX	2.5054	-	AU
Moderna, Inc. MRNA.US	3.7087	-	US
Lonza Group AG LONN.SW	-	-	CH

Entreprise

Ratio P/B

Différence de Ratio P/B

Pays